| Literature DB >> 34526604 |
Yong Zhu1, Yingfan Mao2, Jun Chen3, Yudong Qiu4, Yue Guan5, Zhongqiu Wang6, Jian He7.
Abstract
To investigate the ability of CT-based radiomics signature for pre-and postoperatively predicting the early recurrence of intrahepatic mass-forming cholangiocarcinoma (IMCC) and develop radiomics-based prediction models. Institutional review board approved this study. Clinicopathological characteristics, contrast-enhanced CT images, and radiomics features of 125 IMCC patients (35 with early recurrence and 90 with non-early recurrence) were retrospectively reviewed. In the training set of 92 patients, preoperative model, pathological model, and combined model were developed by multivariate logistic regression analysis to predict the early recurrence (≤ 6 months) of IMCC, and the prediction performance of different models were compared using the Delong test. The developed models were validated by assessing their prediction performance in test set of 33 patients. Multivariate logistic regression analysis identified solitary, differentiation, energy- arterial phase (AP), inertia-AP, and percentile50th-portal venous phase (PV) to construct combined model for predicting early recurrence of IMCC [the area under the curve (AUC) = 0.917; 95% CI 0.840-0.965]. While the AUC of pathological model and preoperative model were 0.741 (95% CI 0.637-0.828) and 0.844 (95% CI 0.751-0.912), respectively. The AUC of the combined model was significantly higher than that of the preoperative model (p = 0.049) or pathological model (p = 0.002) in training set. In test set, the combined model also showed higher prediction performance. CT-based radiomics signature is a powerful predictor for early recurrence of IMCC. Preoperative model (constructed with homogeneity-AP and standard deviation-AP) and combined model (constructed with solitary, differentiation, energy-AP, inertia-AP, and percentile50th-PV) can improve the accuracy for pre-and postoperatively predicting the early recurrence of IMCC.Entities:
Mesh:
Year: 2021 PMID: 34526604 PMCID: PMC8443588 DOI: 10.1038/s41598-021-97796-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart showing inclusion and exclusion of subjects for this study. ICC intrahepatic cholangiocarcinoma, IMCC intrahepatic mass-forming cholangiocarcinoma, TACE transarterial chemoembolization, PEI percutaneous ethanol injection, RFA radiofrequency ablation.
Comparison of clinicopathological characteristics of patients with IMCC with early recurrence and non-early recurrence in training set.
| Clinical-pathological characteristics | Total | Early recurrence | Non-early recurrence | |
|---|---|---|---|---|
| Age (range, years) | 58.37 ± 9.97 (34–79) | 60.54 ± 12.54 (34–79) | 57.57 ± 8.82 (34–77) | 0.234 |
| Gender (male/female) | 49/43 | 12/12 | 37/31 | 0.710 |
| Carcinoembryonic antigen (> / ≤ 5 ng/ml) | 18/74 | 4/20 | 14/54 | 0.677 |
| Carbohydrate antigen 19-9 (> / ≤ 37 U/ml) | 45/47 | 11/13 | 34/34 | 0.726 |
| Carbohydrate antigen 125 (> / ≤ 35 U/ml) | 15/77 | 4/20 | 11/57 | 0.955 |
| Abdominal pain (with/without) | 38/54 | 12/12 | 26/42 | 0.314 |
| HBV + (yes/no) | 57/35 | 17/7 | 40/28 | 0.297 |
| Solitary (yes/no) | 71/21 | 14/10 | 57/11 | 0.011* |
| Size (range, cm) | 5.82 ± 2.65(1.5–12.0) | 6.85 ± 2.96(2.4–12.0) | 5.44 ± 2.44(1.5–12.0) | 0.021* |
| Differentiation | 0.025* | |||
| Well to moderately differentiated | 56 | 10 | 46 | |
| Poorly to undifferentiated | 36 | 14 | 22 | |
| Vascular invasion (yes/no) | 34/58 | 12/12 | 22/46 | 0.124 |
| Neurological invasion (yes/no) | 64/28 | 18/6 | 46/22 | 0.501 |
| Membrane invasion (yes/no) | 47/45 | 17/7 | 30/38 | 0.024* |
| Tumor stage (I–II/III–IV) | 58/34 | 12/12 | 46/22 | 0.124 |
| T stage | 0.583 | |||
| T1–2 | 69 | 17 | 52 | |
| T3–4 | 23 | 7 | 16 | |
| N stage (N0/N1) | 68/24 | 16/8 | 52/16 | 0.347 |
TNM stage according to Japanese TNM stage of intrahepatic cholangiocarcinoma.
*p < 0.05.
Figure 2Kaplan–Meier survival curves of IMCC patients with and without early recurrence in the training set (a) and test set (b).
Logistic regression analysis for predicting early recurrence of IMCC based on basic CT imaging features, radiomics features and clinical indicators (Preoperative model).
| Preoperative model | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Hazard ratio | Hazard ratio | |||
| Plain CT value-mean | 0.356 | 0.968 (0.904,1.037) | ||
| Plain tumor-liver ratio | 0.927 | 1.002 (0.959,1.047) | ||
| AP CT value-mean | 0.894 | 0.997 (0.958,1.038) | ||
| AP tumor-liver ratio | 0.798 | 1.005 (0.969,1.041) | ||
| PV CT value-mean | 0.036* | 0.975 (0.952,0.998) | ||
| PV tumor-liver ratio | 0.532 | 0.994 (0.976,1.012) | ||
| EP CT value-mean | 0.036* | 0.973 (0.949,0.998) | ||
| EP tumor-liver ratio | 0.226 | 0.983 (0.955,1.011) | ||
| Intratumoral artery | 0.866 | 0.922 (0.358,2.374) | ||
| Liver surface contour | 0.846 | 1.100 (0.419,2.886) | ||
| Bile duct dilatation | 0.425 | 0.672 (0.254,1.783) | ||
| Homogeneity-AP | / | / | 0.030* | 0.000 (0.000,0.045) |
| Standard deviation-AP | / | / | 0.007* | 1.355(1.085,1.692) |
| Age | 0.234 | 1.030 (0.981,1.082) | ||
| Gender | 0.710 | 1.267 (0.499,3.218) | ||
| CEA | 0.677 | 0.771 (0.227,2.623) | ||
| CA199 | 0.726 | 0.872 (0.342,2.221) | ||
| CA125 | 0.955 | 0.993 (0.270,3.230) | ||
| Abdominal pain | 0.314 | 1.615 (0.632,4.126) | ||
| HBV | 0.297 | 1.700 (0.623,4.640) | ||
PV portal venous phase, EP equilibrium phase.
*p < 0.05, AP arterial phase.
Logistic regression analysis for predicting early recurrence of IMCC based on pathological characteristics (Pathological model).
| Pathological features | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Hazard ratio | Hazard ratio | |||
| Solitary | 0.011* | 3.701 (1.312,10.439) | 0.034* | 3.285 (1.092,9.886) |
| Size | 0.021* | 1.236 (1.032,1.480) | ||
| Differentiation | 0.025* | 2.927 (1.124,7.625) | ||
| Vascular invasion | 0.124 | 2.238 (0.864,5.794) | ||
| Neurological invasion | 0.501 | 1.435 (0.500,4.118) | ||
| Membrane invasion | 0.024* | 3.266 (1.198,8.903) | 0.027* | 3.309 (1.143,9.581) |
| Tumor staging | 0.124 | 2.091 (0.810,5.395) | ||
| T stage | 0.583 | 1.338 (0.471,3.799) | ||
| N stage | 0.347 | 1.767 (0.634,4.920) | ||
*p < 0.05.
Logistic regression analysis for predicting early recurrence of IMCC based on pathological characteristics, preoperative CT features and clinical indicators (Combined model).
| All | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Hazard ratio | Hazard ratio | |||
| Solitary | 0.013* | 3.701 (1.312,10.439) | 0.013* | 10.000 (1.633,61.214) |
| Size | 0.021* | 1.236 (1.032,1.480) | ||
| Differentiation | 0.028* | 2.927 (1.124,7.625) | 0.020* | 6.500 (1.337,31.609) |
| Membrane invasion | 0.021* | 3.266 (1.198,8.903) | ||
| PV CT value-mean | 0.036* | 0.975 (0.952,0.998) | ||
| EP CT value-mean | 0.036* | 0.973 (0.949,0.998) | ||
| Energy-AP | / | / | 0.015* | 0.300 (0.300,0.055) |
| Inertia-AP | / | / | 0.036* | 0.720 (0.530,0.978) |
| Percentile50th-PV | / | / | 0.044* | 0.911 (0.832,0.997) |
PV portal venous phase, EP equilibrium phase.
*p < 0.05.
Figure 3Delong non-parametric approach, AUC estimates for predicting early recurrence of IMCC were compared between different prediction models in the training set (a) and test set (b).
Predictive performance of the radiomics signature and the two prediction models for the discrimination of early recurrence in training set and test set.
| Variables and models | SEN | SPE | ACC | AUC (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| 1 versus 2 | 1 versus 3 | 2 versus 3 | ||||||
| Training set | 1. Preoperative model | 0.916 | 0.646 | 0.716 | 0.844 (0.751,0.912) | 0.144 | 0.049* | 0.002* |
| 2. Pathological model | 0.625 | 0.767 | 0.730 | 0.741 (0.637,0.828) | ||||
| 3. Combined model | 0.833 | 0.892 | 0.877 | 0.917 (0.840,0.965) | ||||
| Test set | 1. Preoperative model | 0.909 | 0.591 | 0.697 | 0.793 (0.617, 0.914) | 0.911 | 0.099 | 0.157 |
| 2. Pathological model | 0.636 | 0.818 | 0.757 | 0.781 (0.603, 0.905) | ||||
| 3. Combined model | 0.818 | 0.909 | 0.878 | 0.897 (0.741, 0.975) | ||||
AUC area under the curve, CI confidence interval.
*p < 0.05.
Figure 4Decision Curve Analysis in the training set (a) and test set (b), decision curves of the pathological model, preoperative model and combined model.